Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Suspended 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 1Colorectal Neoplasms 1

Interventions

Specimen Handling 642pembrolizumab 565Magnetic Resonance Spectroscopy 548Carboplatin 426Cisplatin 377Cyclophosphamide 374Biopsy 365Paclitaxel 306Nivolumab 303Gemcitabine 303Radiotherapy 274Bevacizumab 240Dexamethasone 209fludarabine 207Docetaxel 191durvalumab 183atezolizumab 177Oxaliplatin 174venetoclax 168Fluorouracil 167Rituximab 166Pemetrexed 164Capecitabine 161Radiation 159Doxorubicin 159Radiosurgery 150Etoposide 137Ipilimumab 135Leucovorin 133Lenalidomide 132

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Riluzole × 90 days × Clear all
NCT03722680 2026-05-20

RILUZOX-01

UNICANCER

Phase 2 Suspended
80 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT01303341 2026-04-13

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
35 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡